Table 1.
IL-11R expression in leukemia and lymphoma bone marrow samples.
| Case#: | Diagnosis: | WBC | BM disease involvement | IL-11Rα WBC | IL-11Rα vessels | Other comments: |
|---|---|---|---|---|---|---|
| 1 | Normal BM | N/A | 0% | neg | neg | |
| 2 | Normal BM | N/A | 0% | neg | neg | |
| 3 | Normal BM | N/A | 0% | neg | N/A | |
|
| ||||||
| 4 | CLL | 16.9 | 61% | pos | N/A | 59% lymphocytes |
| 5 | CLL | 4.7 | 88% | pos | N/A | 88% lymphocytes |
| 6 | Low-grade B-Lymphoma | 4.4 | 30% | neg | pos wk | 12% lymphocytes |
| 7 | B-ALL | 13.3 | 89% | neg | pos | |
|
| ||||||
| 8 | Therapy related MDS | 16.5 | 6% | neg | neg | History of prostate, Merkel, basal, and squamous cell cancer |
| 9 | MDS-RARS | 4.2 | 1% | neg | N/A | |
| 10 | MDS, RCMD | 3.9 | 1% | neg | pos | |
| 11 | MDS-RCMD | 5.9 | 2% | neg | pos | |
| 12 | CMML-2 | 113 | 18% | neg | N/A | History of breast cancer |
| 13 | CMML-2 | 85.8 | 11% | pos | pos | |
|
| ||||||
| 14 | AML-MRC (RAEB-T) | 2.9 | 23% | neg | pos | AML with myelodysplasia related changes (WHO) |
| 15 | AML evolve from MPN | 1.1 | 30% | pos | pos | MPN in 2000, JAK2 negative, AML not treated yet |
| 16 | AML-MO | 10.2 | 55% | wk pos | N/A | |
| 17 | AML-M1 | 194.4 | 97% | neg | N/A | NPM1 mutation, FLT3 internal tandem duplication |
| 18 | AML-M1 | 20.9 | 66% | neg | N/A | |
| 19 | AML-M1 | 0.7 | 87% | pos | N/A | Complex cytogenetics/karyotype, FLT3 wild type |
| 20 | AML-M1 | 12.8 | 85% | pos | pos | Untreated |
| 21 | AML-M2 | N/A | 30% | neg | N/A | |
| 22 | AML-M3/APL | 1.6 | 32% | neg | N/A | Untreated |
| 23 | AML-M3/APL | 40.7 | 91% | focal pos | N/A | |
| 24 | AML-M3/APL | 5.5 | 55% | focal pos | pos | |
| 25 | AML-MRC (M4) | 39.7 | 61% | neg | N/A | Newly diagnosed, Untreated |
| 26 | AML-M4 | 25.9 | 78% | neg | N/A | Untreated |
| 27 | AML-M4 | 88.9 | 33% | pos | N/A | Arising from CMML |
| 28 | AML-M4 | 5.7 | 26% | wk pos | N/A | FLT3 internal tandem duplication |
| 29 | Therapy related AML-M5 | 43.6 | 30% | pos | N/A | History of prostate adenocarcinoma, radiation only |
| 30 | AML-M5 | 2.9 | 68% | wk pos | pos | |
| 31 | AML-M5 | 36.7 | 80% | pos | pos | Untreated |
| 32 | AML-M5 | 13.8 | 71% | pos | N/A | FLT3 internal tandem duplication |
| 33 | AML-M5 | 100.2 | 85% | wk pos | N/A | |
| 34 | AML-M6 | 3.1 | 88% | pos | pos | Untreate |
| 35 | AML | 85.2 | 36% | wk pos | N/A | Previously treated, refractory |
| 36 | AML | 1.2 | 79% | pos | N/A | |
| 37 | AML-MRC | 3.7 | 57% | neg | N/A | |
| 38 | AML-MRC | 2.8 | 25% | neg | N/A | Newly diagnosed, untreated |
| 39 | AML-MRC | 15.4 | 77% | neg | pos | Treated with chemotherapy, not responding |
| 40 | AML refractory | 1.1 | 70% | neg | N/A | Treated with 6 courses of chemotherapy |
| 41 | AML relapse | 7.7 | 90% | focal pos wk | pos | Treated ovarian carcinoma 2009, treated AML |
| 42 | AML refractory, relapsing | 3.3 | 41% | neg | pos | Treated with chemothery |
| 43 | AML inv16, relapse | 5.8 | 49% | neg | pos | Treated |
| 44 | AML relapse | 4.7 | 70% | neg | pos | Treated |
| 45 | AML refractory | 2.2 | 27% | neg | N/A | Treated |
| 46 | AML relapse | 0.5 | 44% | neg | N/A | Treated |
|
| ||||||
| Total # of specimens: 46 | ||||||
White blood cell (WBC) counts and bone marrow (BM) blast percentage of each sample are indicated. The approximate levels of IL-11R were estimated by positively staining cells in the specimens. Staining status of blood vessels is listed or marked as N/A if no blood vessels were visible in a particular sample. Previous cancer history and current treatment status, if known, are also indicated.
Abbrevations: negative (neg); positive (pos); not available (N/A); weak (wk); bone marrow (BM); chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); myelodysplastic syndrome (MDS); AML with MDS-related changes (MRC); refractory anemia with ring sideroblasts (RARS); refractory cytopenia with myltilineage dysplasia (RCMD); refractory anemia with excess blasts in transformation (RAEB-T); chronic myelomonocytic leukemia (CMML); acute myeloid leukemia (AML); myeloproliferative neoplasm (MPN); acute promyelocytic leukemia (APL).